ArticleFrontiers in immunology2026
Integrated post-GWAS, single-cell, and functional analyses prioritize
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-genome-wide association study (GWAS) interpretation of osteoarthritis (OA) increasingly requires integration with single-cell biology because many risk loci likely act through sterile inflammatory remodeling, regulatory and inflammatory chondrocyte states, and tissue-stress biology rather than through large disease-stage expression shifts. We therefore asked whether a published Transformer-based post-GWAS prioritization strategy could refine a multi-gene chr12 susceptibility locus into a tractable Methods: Using combined hip and knee osteoarthritis summary statistics (213,839 cases and 1,080,481 controls), we built a transfer-learning variant-prioritization layer that scored 20,651,210 variants with 21 engineered features, combined these with LDSC, positional MAGMA, fibroblast and muscle eMAGMA, six-tissue SMR, and fine-mapping, and then integrated the prioritized locus with a 56,000-cell chondrocyte atlas, independent OA cartilage expression resources, OA primary-tissue eQTL maps, and ATDC5 perturbation experiments. Results: The prioritization model, used solely as a ranking layer, assigned a high prioritization score (≥ 0.99) to 17,150 variants, including the chr12 lead rs11611450 (prioritization score 0.999853), and highlighted 6,275 additional non-genome-wide-significant high-priority variants. Positional MAGMA nominated eight Bonferroni-significant genes, and eMAGMA nominated four genes in skeletal muscle and seven in fibroblasts. Within the rs11611450-linked five-gene cluster, Conclusions: This staged analysis nominates
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.